Trial not started; change in Sponsor, a new trial to be registered by the new Sponsor

This Phase 2a, multicenter, randomized, double-blind, placebo-controlled study examines subcutaneous dose of PF-06480605 150 mg administered every 4 weeks in participants with moderate to severe active Crohn's Disease to characterize safety, efficacy, pharmacokinetics, and immunogenicity

Inclusion Criteria:

• Confirmed diagnosis of ileocolonic or colonic CD with at least 3 months or longer prior to the baseline;
• Central read total SES-CD score of ≥7. For isolated ileal disease, SES-CD total score should be ≥4;
• An average daily liquid/very soft SF ≥4 or daily AP score ≥2.0;
• CDAI between 220 and 450 inclusive;
• Must have inadequate response to, loss of response to, or intolerance to at least one conventional therapy for CD

Exclusion Criteria:

• Diagnosis of indeterminate colitis, microscopic colitis, ischemic colitis, infectious colitis, radiation colitis, diverticular disease, UC, or clinical findings suggestive of UC;
• Presence of active (draining) fistulae or intra-abdominal or perineal abscesses;
• Strictures or stenosis with obstructive symptoms;
• Short bowel syndrome;
• History of bowel perforation requiring surgical intervention within the past 12 months prior to baseline;
• Previous bowel surgery resulting in an existing stoma. Participants who have a j-pouch are excluded, as a j-pouch can result in a stoma;
• History of bowel surgery within 6 months prior to baseline.

Pfizer will provide access to individual de-identified participant data and related study documents (e.g. protocol, Statistical Analysis Plan (SAP), Clinical Study Report (CSR)) upon request from qualified researchers, and subject to certain criteria, conditions, and exceptions. Further details on Pfizer's data sharing criteria and process for requesting access can be found at: https://www.pfizer.com/science/clinical\_trials/trial\_data\_and\_results/data\_requests.